





15/06/2020

# Test report L20/0542BC.1

# Evaluation of the effectiveness of

# GVK Geliksi GeveDesi Pro

bovine coronavirus (BCoV) (surrogate of human coronaviruses) Test virus:

Method: EN 14476:2013+A2:2019 (clean conditions)

> quantitative suspension test for the evaluation of virucidal activity of chemical disinfectants and antiseptics used in human medicine (phase 2/ step 1)

Sponsor:

**GVK Coating Technology Oy** Muddaistentie 261 F-21600 Parainen Finland

Norderoog 2, DE - 28259 Bremen Tel.: +49 40-557631-0, Fax: +49 40-557631-11

info@brillhygiene.com, http://www.brillhygiene.com

Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page 2 of 20

### 1. Identification of test laboratory

Dr. Brill + Partner GmbH Institute for Hygiene and Microbiology, Norderoog 2, DE - 28259 Bremen

### 2. Identification of sample

| Sponsor                                         | GVK Coating Technology Oy                                     |
|-------------------------------------------------|---------------------------------------------------------------|
| Name of product                                 | GVK Geliksi GeveDesi Pro                                      |
| Confirmation no.                                | 214214                                                        |
| Product diluent recommended by the manufacturer | -                                                             |
| Batch number                                    | 2000126                                                       |
| Application                                     | hand disinfection                                             |
| Production date                                 | -                                                             |
| Expiry date                                     | -                                                             |
| Active compound (s) (100 g)                     | ethanol, 70%                                                  |
| Appearance, odour                               | Clear, colorless liquid product specific                      |
| pH-values                                       | undiluted: 9.41 (20 °C)                                       |
| Storage conditions                              | room temperature in the dark<br>(area with restricted access) |
| Date of arrival in the laboratory               | 30/04/2020                                                    |

### 3. Materials

### 3.1 Culture medium and reagents

- Eagle's Minimum Essential Medium with Earle's BSS (EMEM, Biozym Scientific GmbH, catalogue no. 880121)
- fetal calf serum (Thermo Fisher, article no. CH30160.02)
- 1.4 % formaldehyde solution (dilution of Roti®-Histofix 4 %, Carl Roth GmbH)
- Aqua bidest. (SG ultrapure water system, type Ultra Clear; serial no. 86996-1)
- PBS (Invitrogen, article no. 18912-014)
- BSA (Sigma-Aldrich-Chemie GmbH, article no. CA-2153).

<sup>\*</sup>Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE − 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. Dr. Brill + Partner GmbH 2020







Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page 3 of 20

### 3.2 Virus and cells


The bovine coronavirus strain L9 was obtained by Dr. G. Zimmer, Institute of Virology at the School of Veterinary Medicine Hannover (Tierärztliche Hochschule, DE - 30559 Hannover).

The *U373 cells* (passage 12) were as well obtained by Dr. G. Zimmer, Institute of Virology at the School of Veterinary Medicine Hannover (Tierärztliche Hochschule, DE - 30559 Hannover).

The cells were inspected regularly for morphological alterations and for contamination by mycoplasmas. No morphological alterations of cells and no contamination by mycoplasmas could be detected.

### 3.3 Apparatus, glassware and small items of equipment

- CO<sub>2</sub> incubator
- Agitator (Vortex Genie Mixer, type G 560E)
- pH measurement 315i (WTW, article no. 2A10-100)
- Centrifuge (Sigma-Aldrich-Chemie GmbH, type 113)
- Microscope (Olympus, type CK 30)
- Centrifuge 5804 R (Eppendorf AG)
- Water bath (JULABO, Julabo U 3)
- Adjustable and fixed-volume pipettes (Eppendorf AG)
- Polysterol 96-well microtitre plate (Nunc GmbH & Co. KG, Wiesbaden)
- Cell culture flask (Nunc GmbH & Co. KG, Wiesbaden)
- Sealed test tubes (Sarstedt AG & Co., Nümbrecht).









Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page **4 of 20** 

### 4. Experimental conditions

| Test temperature                                                                       | 20 °C ± 1.0 °C                                                                            |
|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Concentration of test product                                                          | undiluted (80.0 %) and as 50.0 % and 10.0 % (demonstration of non-active range) solutions |
| Appearance of product dilutions                                                        | no precipitation                                                                          |
| Contact times                                                                          | 30 seconds and 30 minutes                                                                 |
| Interfering substance                                                                  | 0.3 g/l bovine serum albumin (clean conditions, EN 14476)                                 |
| Procedure to stop action of disinfectant                                               | immediate dilution                                                                        |
| Diluent                                                                                | Aqua bidest.                                                                              |
| Stability of product in the mix with virus and interfering substance (80.0 % solution) | minor clouding, no precipitation                                                          |
| Virus strain                                                                           | bovine coronavirus strain L9                                                              |
| Date of testing                                                                        | 07/05/2020 — 15/06/2020                                                                   |
| End of testing                                                                         | 15/06/2020                                                                                |


### 5. Methods

### 5.1 Preparation of test virus suspension

To prepare the test virus suspension, *U373* cells were cultivated in a 175 cm<sup>2</sup> flask with in EMEM supplemented with L-glutamine, non-essential amino acids and sodium pyruvate and 10 % fetal calf serum. Before virus infection, cells were washed two times with phosphate buffered saline (PBS), incubated for 3 h with EMEM without FCS and were washed once with EMEM supplemented with trypsin. For virus production, BCoV strain L9 was added to the prepared monolayer. After an incubation period of 24 to 48 hours (cells showed a constant cytopathic effect), cells were lysed by a rapid freeze/thaw cycle. Cellular debris was removed by low speed centrifugation. After aliquotation of the supernatant, test virus suspension was stored at –80 °C.

### 5.2 Preparation of disinfectant (dilutions)

The test product was evaluated undiluted. Due to the addition of interfering substance and test virus suspension an 80.0 % solution resulted.









Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page **5 of 20** 

Furthermore, the product was evaluated as 50.0 % and 10.0 % solutions (demonstrating of non-active range). These solutions were prepared with Aqua bidest. immediately before the inactivation tests.

### 5.3 Infectivity assay

Infectivity was determined by means of end point dilution titration using the microtitre process. For this, samples were immediately diluted at the end of the exposure time with ice-cold EMEM with trypsin and 100  $\mu$ l of each dilution were placed in eight wells of a sterile polystyrene flat bottomed plate with a preformed *U373* monolayer. Before addition of virus, cells were washed twice with EMEM and incubated for 3 h with 100  $\mu$ l EMEM with trypsin. Incubation was at 37 °C in a CO<sub>2</sub>-atmosphere (5.0 % CO<sub>2</sub> - content). Finally, cultures were observed for cytopathic effects for six days of inoculation. The infectious dose (TCID<sub>50</sub>) was calculated according to the method of Spearman (2) and Kärber (3).

### 5.4 Calculation and verification of virucidal activity

The virucidal activity of the test disinfectant was evaluated by calculating the decrease in titre in comparison with the control titration without disinfectant. The difference is given as reduction factor (RF).

According to the EN 14476, a disinfectant or a disinfectant solution at a particular concentration is having virus-inactivating efficacy if the titre is reduced at least by 4  $\log_{10}$  steps within the recommended exposure period. This corresponds to an inactivation of  $\geq$  99.99 %.

### 5.5 Inactivation assay

Determination of virucidal activity has been carried out according to EN 5.5. The test product was examined undiluted (80.0 %) and as 50.0 % and 10.0 % (demonstration of non-active range) solutions in Aqua bidest. at 20 °C according to EN 14476. 30 seconds and 30 minutes were chosen as contact time.

Immediately at the end of a chosen contact time, activity of the disinfectant was stopped by dilution to  $10^{-8}$ .

Titrations of the virus control were performed at the beginning of the test and after the longest exposure time (EN 5.5.7). One part by volume of test virus suspension was mixed with one part interfering substance and eight parts by volume of WSH or Aqua bidest. (RTU products).

<sup>\*</sup>Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE — 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request.© Dr. Brill + Partner GmbH 2020







L20/0542BC.1 Test report no: Author: DP Version 01 Date: 15/06/2020

> Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

> > Page **6 of 20**

Furthermore, a cell control (only addition of medium) was incorporated.

Inactivation tests were carried out in sealed test tubes in a water bath at 20 °C  $\pm$  1.0 °C. Aliquots were retained after appropriate exposure times and residual infectivity was determined.

#### 5.6 **Determination of cytotoxicity**

Determination of cytotoxicity was performed according to EN 5.5.4.1.

#### 5.7 Cell sensitivity to virus

For the control of cell sensitivity to virus two parts by volume of water were mixed with eight parts by volume of the lowest apparently non-cytotoxic dilution of the product. This mixture or PBS as control was added to the wells of the microtitre plates with a preformed monolayer of *U373 cells*. After at least one hour, a comparative virus titration was performed on the cells treated in such a manner or treated with PBS only.

#### 5.8 Control of efficacy for suppression of disinfectant's activity

Furthermore, a control of efficiency for suppression of disinfectant's activity was included (EN 5.5.5).

#### 5.9 Reference virus inactivation test

As reference for test validation a 0.7 % formaldehyde solution according to EN 5.5.6 was included. 5, 15, 30 and 60 minutes were chosen as contact times. In addition, cytotoxicity of formaldehyde test solution was determined based on EN 5.5.6.2 with dilutions up to 10<sup>-5</sup>.

## Verification of the methodology

The following criteria as mentioned in EN 5.7 were fulfilled:

- a) The titre of the test virus suspension allowed the determination of  $a \ge 4 \log_{10}$  reduction (maximal virus reduction  $\geq 5.63 \pm 0.45$ )
- b) The test product (80.0 %) showed no cytotoxicity in the 1:10 dilutions thus allowing the detection of a 4 log<sub>10</sub> reduction of virus titre.

<sup>\*</sup>Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE - 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request.© Dr. Brill + Partner GmbH 2020







Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page 7 of 20

- c) The comparative titration on pre-treated (disinfectant) and non-pre-treated (PBS) U373 cells showed no significant difference (< 1 log<sub>10</sub>; EN 5.7) of virus titre:  $7.38 \pm 0.53$  (PBS) versus  $7.13 \pm 0.49$  (1:10 dilutions of disinfectant as 80.0 % solution) log<sub>10</sub> TCID<sub>50</sub>/ml.
- d) The control of efficacy for suppression of disinfectant's activity (80.0 %) showed no decrease ( $\leq$  0.5 log<sub>10</sub>; EN 5.5.5.1) in virus titre (6.88  $\pm$  0.37 versus 7.13  $\pm$  0.45 log<sub>10</sub> TCID<sub>50</sub>/ml).

Since these criteria according EN 5.7 were fulfilled, examination with bovine coronavirus according to EN 14476 is valid.

### 7. Results

Results of examination are shown in tables 1 to 7. Tables 1 to 6 demonstrate the raw data, whereas tables 7 (a+b) give a summary of results.

The undiluted test product in an 80.0 % assay was able to inactivate bovine coronavirus after 30 seconds of exposure time under clean conditions (table 1). The reduction factor was  $\geq 5.63 \pm 0.45$ . This corresponded to an inactivation of  $\geq 99.999$  %.

The test product as 50.0 % was also able to inactivate bovine coronavirus after 30 seconds of exposure time under clean conditions (table 2). The reduction factor was  $\geq 5.63 \pm 0.45$ . This corresponded to an inactivation of  $\geq 99.999$  %.

The test product as 10.0 % solution was not able to inactivate bovine coronavirus within 30 minutes of exposure time under clean conditions (table 3).







Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page 8 of 20

### 8. Conclusion

The hand disinfectant GVK Geliksi GeveDesi Pro tested undiluted demonstrated activity against bovine coronavirus after an exposure time of 30 seconds under clean conditions. Therefore, the hand disinfectant GVK Geliksi GeveDesi Pro can be declared as active against bovine coronavirus as follows:

undiluted 30 seconds clean conditions

Bremen, 15/06/2020

Dr. Britta Becker Head of Laboratory
 Dr. Dajana Paulmann Scientific Project Manager







Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page **9 of 20** 

### 9. Quality control

The Quality Assurance of the results was maintained by performing the determination of the virus-inactivating properties of the disinfectant in accordance with Good Laboratory Practice regulations:

- 1) Chemicals Act of Germany, Appendix 1, dating of 01.08 1994 (BGBI. I, 1994, page 1703). Appendix revised at 14. 05. 1997 (BGBI. I, 1997, page 1060).
- 2) OECD Principles of Good Laboratory Practice (revised 1997); OECD Environmental Health and Safety Publications; Series on Principles of Good Laboratory Practice and Compliance Monitoring Number 1. Environment Directorate, Organization for Economic Co-operation and Development, Paris 1998.


The plausibility of the results was additionally confirmed by controls incorporated in the inactivation assays.

### 10. Records to be maintained

All testing data, protocol, protocol modifications, the final report, and correspondence between Dr. Brill + Partner GmbH and the sponsor will be stored in the archives at Dr. Brill + Partner GmbH.

The use of the Dr. Brill + Partner GmbH name, logo or any other representation of Dr. Brill + Partner GmbH, other than distribution of this report in it's entirely, without the written approval of Dr. Brill + Partner GmbH is prohibited. In addition, Dr. Brill + Partner GmbH may not be referred to in any form of promotional materials, press releases, advertising or similar materials (whether by print, broadcast, communication or electronic means) without the express permission of Dr. Brill + Partner GmbH.

The test results in this test report relate only to the items examined.









Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page 10 of 20

### 11. Literature

- 1. EN 14476:2013+A2:2019: Chemical disinfectants and antiseptics Quantitative suspension test for the evaluation of virucidal activity of chemicals disinfectants and antiseptics in human medicine test Test method and requirements (phase 2, step 1)
- 2. Spearman, C.: The method of `right or wrong cases` (constant stimuli) without Gauss's formulae.

  Brit J Psychol; 2 1908, 227-242
- 3. Kärber, G.: Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharmak; 162, 1931, 480-487







Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page 11 of 20

### Appendix:

### **Legend to the Tables**

Table 1: Raw data for GVK Geliksi GeveDesi Pro (80.0 %) tested against bovine coronavirus

Raw data for GVK Geliksi GeveDesi Pro (50.0 %) tested against bovine coronavirus

Raw data for GVK Geliksi GeveDesi Pro (10.0 %) tested against bovine coronavirus

Raw data for formaldehyde solution (0.7 %) tested against bovine coronavirus

Raw data for control of efficacy for suppression of disinfectant's activity (80.0 %)


Raw data (bovine coronavirus) for cell sensitivity (80.0 %)

Table 7 (a+b): Summary of results with GVK Geliksi GeveDesi Pro and bovine coronavirus

### **Legend to the Figures**

Figure 1: Virus-inactivating properties of GVK Geliksi GeveDesi Pro (80.0 %)

Figure 2: Virus-inactivating properties of formaldehyde (0.7 %)







Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page 12 of 20

# Table 1: Raw data for GVK Geliksi GeveDesi Pro (80.0 %) tested against bovine coronavirus at 20 °C (quantal test; 8 wells) (#6607)

| D 1 4                     |               | Interfering<br>substance | Contact time | ontact time Dilutions (log <sub>10</sub> ) |              |              |              |              |              |              |              |              |  |
|---------------------------|---------------|--------------------------|--------------|--------------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--|
| Product                   | Concentration |                          | (min)        | 1                                          | 2            | 3            | 4            | 5            | 6            | 7            | 8            | 9            |  |
|                           |               | 0.5                      | 0000<br>0000 | 0000<br>0000                               | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | n.d.         | n.d.         | n.d.         |              |  |
| test product              | 80.0 %        | clean conditions         | 2            | n.d.                                       | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         |  |
| test product              | 00.0 /0       |                          | 15           | n.a.                                       | n.d.         |  |
|                           |               |                          | 30           | n.d.                                       | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         |  |
| test product cytotoxicity | 80.0 %        | clean conditions         | n.a.         | 0000<br>0000                               | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | n.d.         | n.d.         | n.d.         | n.d.         |  |
| virus                     | n a           | clean conditions         | 0            | 4444<br>4444                               | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4440 | 0000<br>0004 | 0000<br>0000 | 0000<br>0000 |  |
| control                   | n.a.          |                          | 60           | 4444<br>4444                               | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 0404<br>4040 | 0000<br>0040 | 0000<br>0000 | 0000<br>0000 |  |

n.a. = not applicable

0 = no virus present; t = cytotoxic

n.d. = not done

<sup>\*</sup> Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request.© Dr. Brill + Partner GmbH 2020





Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page 13 of 20

# Table 2: Raw data for GVK Geliksi GeveDesi Pro (50.0 %) tested against bovine coronavirus at 20 °C (quantal test; 8 wells) (#6607)

| Duradurat                 | Composition   | Interfering<br>substance | Contact time | ontact time Dilutions (log <sub>10</sub> ) |              |              |              |              |              |              |              |              |  |
|---------------------------|---------------|--------------------------|--------------|--------------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--|
| Product                   | Concentration |                          | (min)        | 1                                          | 2            | 3            | 4            | 5            | 6            | 7            | 8            | 9            |  |
|                           |               | 0.5                      | 0000<br>0000 | 0000<br>0000                               | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | n.d.         | n.d.         | n.d.         |              |  |
| test product              | 50.0 %        | clean conditions         | 2            | n.d.                                       | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         |  |
| test product              | 30.0 /0       | clean conditions         | 15           | n.a.                                       | n.d.         |  |
|                           |               |                          | 30           | n.d.                                       | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         |  |
| test product cytotoxicity | 50.0 %        | clean conditions         | n.a.         | 0000<br>0000                               | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | n.d.         | n.d.         | n.d.         | n.d.         |  |
| virus                     | n a           | clean conditions         | 0            | 4444<br>4444                               | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4440 | 0000<br>0004 | 0000<br>0000 | 0000<br>0000 |  |
| control                   | n.a.          | clean conditions         | 60           | 4444<br>4444                               | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 0404<br>4040 | 0000<br>0040 | 0000<br>0000 | 0000<br>0000 |  |

n.a. = not applicable

0 = no virus present; t = cytotoxic

n.d. = not done

<sup>\*</sup> Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request.© Dr. Brill + Partner GmbH 2020





> Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

> > Page **14 of 20**

15/06/2020

# Table 3: Raw data for GVK Geliksi GeveDesi Pro (10.0 %) tested against bovine coronavirus at 20 °C (quantal test; 8 wells) (#6607)

| Dura durat                | Composition   | Interfering<br>substance | Contact time | Dilutions (log <sub>10</sub> ) |              |              |              |              |              |              |              |              |  |
|---------------------------|---------------|--------------------------|--------------|--------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--|
| Product                   | Concentration |                          | (min)        | 1                              | 2            | 3            | 4            | 5            | 6            | 7            | 8            | 9            |  |
|                           |               |                          | 0.5          | n.d.                           | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         |  |
| test product              | 10.0 %        | clean conditions         | 2            | n.d.                           | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         | n.d.         |  |
| test product              | 10.0 /0       | clean conditions         | 15           | n.a.                           | n.d.         |  |
|                           |               |                          | 30           | n.d.                           | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4400<br>4444 | 0000<br>0000 | 0000<br>0000 | n.d.         |  |
| test product cytotoxicity | 10.0 %        | clean conditions         | n.a.         | 0000<br>0000                   | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | n.d.         | n.d.         | n.d.         | n.d.         |  |
| virus                     | n a           | clean conditions         | 0            | 4444<br>4444                   | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4440 | 0000<br>0004 | 0000<br>0000 | 0000<br>0000 |  |
| control                   | n.a.          |                          | 60           | 4444<br>4444                   | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 0404<br>4040 | 0000<br>0040 | 0000<br>0000 | 0000<br>0000 |  |

n.a. = not applicable

0 = no virus present; t = cytotoxic

n.d. = not done

<sup>\*</sup> Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE - 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2020





L20/0542BC.1 Test report no: Author: DP Version 01 Date:

> Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

> > Page **15 of 20**

15/06/2020

# Table 4: Raw data for formaldehyde solution (0.7 %) tested against bovine coronavirus at 20 °C (quantal test; 8 wells) (#6607)

| Door doorst               | Ctt            | Interfering<br>substance | Contact time |              |              |              |              |              |              |              |              |              |  |
|---------------------------|----------------|--------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--|
| Product                   | Concentration  |                          | (min)        | 1            | 2            | 3            | 4            | 5            | 6            | 7            | 8            | 9            |  |
| 6.7 %                     |                |                          | 5            | tttt<br>tttt | tttt<br>tttt | tttt<br>tttt | 4444<br>0444 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | n.d.         |  |
|                           | 0.7 %          | PBS                      | 15           | tttt<br>tttt | tttt<br>tttt | tttt<br>tttt | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | n.d.         |  |
| formaldehyde              | (m/V)          | L D2                     | 30           | tttt<br>tttt | tttt<br>tttt | tttt<br>tttt | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | n.d.         |  |
|                           |                |                          | 60           | tttt<br>tttt | tttt<br>tttt | tttt<br>tttt | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 | n.d.         |  |
| formaldehyde cytotoxicity | 0.7 %<br>(m/V) | PBS                      | n.a.         | tttt<br>tttt | tttt<br>tttt | tttt<br>tttt | 0000<br>0000 | 0000<br>0000 | n.d.         | n.d.         | n.d.         | n.d.         |  |
| virus                     | n a            | PBS -                    | 0            | n.d.         |  |
| control                   | n.a.           |                          | 60           | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>0444 | 0000<br>0000 | 0000<br>0000 | 0000<br>0000 |  |

n.a. = not applicable

0 = no virus present; t = cytotoxic

n.d. = not done

<sup>\*</sup> Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE - 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2020







Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page **16 of 20** 

Table 5: Raw data for control of efficacy for suppression of disinfectant's activity (80.0 %) (#6607)

| Product                     | Interfering      |              | dilutions (log <sub>10</sub> ) |              |              |              |              |              |              |              |  |  |  |
|-----------------------------|------------------|--------------|--------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--|--|--|
|                             | substance        | 1            | 2                              | 3            | 4            | 5            | 6            | 7            | 8            | 9            |  |  |  |
| test product                | clean conditions | n.d.         | 4444<br>4444                   | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4304<br>0000 | 0000<br>4444 | 0000<br>0000 | n.d.         |  |  |  |
| corresponding virus control | clean conditions | 4444<br>4444 | 4444<br>4444                   | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 0404<br>4040 | 0000<br>0040 | 0000<br>0000 | 0000<br>0000 |  |  |  |

n.a. = not applicable

0 = no virus present; t = cytotoxic

n.d. = not done

DR. BRILL + DR. STEINMANN

1 to 4 = virus present (degree of CPE in 8 cell culture units) (wells of microtitre plates)

Table 6: Raw data (bovine coronavirus) for cell sensitivity (80.0 %) (#6607)

| Product      | Dilution | Dilutions (log <sub>10</sub> ) |              |              |              |              |              |              |              |      |  |  |
|--------------|----------|--------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|------|--|--|
|              |          | 1                              | 2            | 3            | 4            | 5            | 6            | 7            | 8            | 9    |  |  |
| PBS          | -        | 4444<br>4444                   | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4044<br>0400 | 4040<br>0300 | 0000<br>0000 | n.d. |  |  |
| test product | 1:10     | 4444<br>4444                   | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 4444<br>4444 | 0403<br>0400 | 4000<br>0040 | 0000<br>0000 | n.d. |  |  |

n.a. = not applicable

0 = no virus present; t = cytotoxic

n.d. = not done

<sup>\*</sup> Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE - 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2020





Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page **17 of 20** 

# Table 7a: Summary of results with GVK Geliksi GeveDesi Pro and bovine coronavirus

| Product      | Con-      | Interfering      | Level of |            | log <sub>10</sub> To | CID <sub>50</sub> /ml after | min       |          | > 4 log <sub>10</sub> reduction |
|--------------|-----------|------------------|----------|------------|----------------------|-----------------------------|-----------|----------|---------------------------------|
|              | substance | cytotoxicity     | 0.5      | 2          | 15                   | 30                          | 60        | aftermin |                                 |
| test product | 80.0 %    | clean conditions | 1.50     | ≤1.50±0.00 | n.d.                 | n.d.                        | n.d.      | n.d.     | $0.5 (RF \ge 5.63 \pm 0.45)$    |
| test product | 50.0 %    | clean conditions | 1.50     | ≤1.50±0.00 | n.d.                 | n.d.                        | n.d.      | n.d.     | 0.5 (RF ≥ 5.63±0.45)            |
| test product | 10.0 %    | clean conditions | 1.50     | n.d.       | n.d.                 | n.d.                        | 7.25±0.33 | n.d.     | > 30 (RF = 0.00±0.56)           |

n.a. = not applicable n.d. = not done

<sup>\*</sup> Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2020





Test report no:
Author: DP Version 01 Date:

L20/0542BC.1 15/06/2020

Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page 18 of 20

# Table 7b: Summary of results with GVK Geliksi GeveDesi Pro and bovine coronavirus

| Product                          | Con-                    | Interfering      | Level of     |           |            | > 4 log <sub>10</sub> reduction |            |            |                       |
|----------------------------------|-------------------------|------------------|--------------|-----------|------------|---------------------------------|------------|------------|-----------------------|
| Product                          | centration              | substance        | cytotoxicity | 0         | 5          | 15                              | 30         | 60         | after min             |
| formaldehyde                     | 0.7 %<br>(w/v)          | PBS              | 4.50         | n.d.      | ≤5.63±0.45 | ≤4.50±0.00                      | ≤4.50±0.00 | ≤4.50±0.00 | ≥ 15 (RF ≥ 2.88±0.25) |
| virus control                    | n.a.                    | PBS              | n.a.         | n.d.      | n.d.       | n.d.                            | n.d.       | 7.38±0.25  | n.a.                  |
| virus control<br>(+ suppression) | n.a.                    | clean conditions | n.a.         | 7.50±0.35 | n.d.       | n.d.                            | n.d.       | 7.13±0.45  | n.a.                  |
| suppression<br>control           | 80.0 %                  | clean conditions | 1.50         | n.d.      | n.d.       | n.d.                            | 6.88±0.37  | n.d.       | n.a.                  |
| sens. PBS                        | n.a.                    | n.a.             | n.a.         | n.d.      | n.d.       | n.d.                            | n.d.       | 7.38±0.53  | n.a.                  |
| sens. product                    | 80.0 % <b>→</b><br>1:10 | n.a.             | n.a.         | n.d.      | n.d.       | n.d.                            | n.d.       | 7.13±0.49  | n.a.                  |

n.a. = not applicable n.d. = not done

<sup>\*</sup> Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE – 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2020






Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page **19 of 20** 

Figure 1: Virus-inactivating properties of GVK Geliksi GeveDesi Pro (80.0 %)

DR. BRILL + DR. STEINMANN



<sup>\*</sup> Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE - 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2020








Product name: GVK Geliksi GeveDesi Pro Method: EN 14476\*

Page **20 of 20** 

Figure 2: Virus-inactivating properties of formaldehyde (0.7 %)

DR. BRILL + DR. STEINMANN



<sup>\*</sup> Test procedure accredited according to DIN EN ISO/IEC 17025. Test report issued by Dr. Brill + Partner GmbH, Norderoog 2, DE - 28259 Bremen, Germany, Telephone +49. 40. 557631-0, Telefax +49. 40. 557631-11, www.brillhygiene.com. No copying or transmission, in whole or in part, of this test report without the explicit prior written permission. The test results exclusively apply to the tested samples. Information on measurement uncertainty on request. © Dr. Brill + Partner GmbH 2020



